ProCE Banner Activity

FORTE: KRd Induction/Consolidation With ASCT vs 12 Cycles of KRd vs KCd Induction/Consolidation With ASCT in ASCT-Eligible Newly Diagnosed MM

Slideset Download
Conference Coverage
In this premaintenance analysis, KRd regimens improved responses vs KCd in this ongoing phase II trial.

Released: December 06, 2018

Expiration: December 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology